D.E. Shaw & Co’s Lifecore Biomedical LFCR Stock Holding History

D.E. Shaw & Co’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-12,000	Closed	-$146K	–	4578
2013 Q3	$146K	Hold	12,000	–	–	﹤0.01%	4151
2013 Q2	$159K	Buy	+12,000	New	+$166K	﹤0.01%	3803

Other funds holding LFCR

22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Grizzlyrock Capital Chicago, Illinois $143M AUM 6.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co's LFCR Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 37,428 shares — an estimated $306K sold.

D.E. Shaw & Co first reported a position in LFCR in Q3 2015 and held it in 26 quarters. The position peaked at $1.14M in Q2 2021. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

D.E. Shaw & Co reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
D.E. Shaw & Co sold 37,428 Lifecore Biomedical shares in Q1 2026, an estimated $306K.
D.E. Shaw & Co first reported a position in Lifecore Biomedical in Q3 2015 and held it in 26 quarters.
D.E. Shaw & Co's Lifecore Biomedical position peaked at $1.14M in Q2 2021.
105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.